8-K: Ginkgo Bioworks Reports Q1 2026 Results, Divests Biosecurity

Ginkgo Bioworks announced its first quarter 2026 financial results, reporting $19 million in revenue and a GAAP net loss of $76 million, while also completing the divestiture of its Biosecurity business.

Summary

• Ginkgo Bioworks reported first quarter 2026 revenue of $19 million, a 49% decrease from $38 million in the prior year period. Excluding a $7 million non-cash revenue release in Q1 2025, revenue decreased 37% to $19 million from $31 million.
• The company reported a GAAP net loss from continuing operations of $76 million for Q1 2026, an improvement from a $83 million loss in the comparable prior year period.
• Adjusted EBITDA for Q1 2026 was $(42) million, an improvement from $(44) million in Q1 2025.
• Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026, and has presented these results within discontinued operations.
• The company reaffirmed its full-year 2026 expected total cash burn of $(150) million to $(125) million.
• As of March 31, 2026, Ginkgo's cash, cash equivalents, and marketable securities balance was $373 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant revenue decline, despite improvements in Adjusted EBITDA and net loss from continuing operations.

Positives

• Adjusted EBITDA improved to $(42) million from $(44) million in the prior year period.
• GAAP net loss from continuing operations narrowed to $(76) million from $(83) million in the prior year period.
• The company has a strong cash position with $373 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
• Ginkgo is scaling its autonomous lab, Nebula, with plans to double its size in 2026, positioning it as a leader in automated research infrastructure.

Negatives

• Revenue decreased by 49% to $19 million in Q1 2026 compared to $38 million in Q1 2025.
• Excluding a non-cash revenue release in the prior year, revenue still decreased by 37% to $19 million from $31 million.
• The decrease in revenue is attributed to ongoing program rationalization as part of restructuring activities.
• The company reported a GAAP net loss of $76 million from continuing operations in Q1 2026.

Risks

• Volatility in the price of Ginkgo's securities due to changes in the competitive and highly regulated industries.
• Downturns in demand for products using synthetic biology.
• Uncertainty regarding the demand for passive monitoring programs and biosecurity services.
• Changes to the biosecurity industry due to technological advancements, competition, and evolving demands.
• The pace and degree to which autonomous laboratory infrastructure is adopted and displaces manual laboratory work.
• The actual size and growth of addressable markets may differ materially from estimates.
• Potential negative impact on the business from restructuring or failure to realize anticipated savings.

Future Outlook

Ginkgo reaffirms its expected total cash burn of $(150) million to $(125) million for the full year 2026. The company aims to double the size of its autonomous lab, Nebula, in 2026.

Management Comments

• "We believe autonomous labs will replace the lab bench more quickly than people think," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks.
• "Nebula is already the world's largest autonomous lab with the ability to run real customer science around the clock and we're targeting to double its size this year."
• "Ginkgo is singularly focused on leading the transition from the lab bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."

Industry Context

StockSavvy.ai notes that Ginkgo Bioworks' focus on autonomous labs and integration with AI models aligns with broader industry trends in drug discovery and industrial biotechnology, aiming to increase efficiency and accelerate research.

Comparison to Industry Standards

• The company's stated goal to double the size of its autonomous lab, Nebula, in 2026 positions it as a significant player in the scaling of automated laboratory infrastructure.
• Ginkgo's strategy to integrate its platform with AI models for drug discovery is a key development in the synthetic biology sector, where many companies are exploring AI-driven research.

Stakeholder Impact

• Shareholders may be concerned by the significant revenue decline, although improvements in loss metrics and a strong cash position could be viewed positively.
• Employees may be impacted by ongoing restructuring activities mentioned as a reason for revenue decrease.
• Customers may benefit from the continued development and scaling of Ginkgo's autonomous lab capabilities, potentially leading to faster and more efficient research outcomes.

Next Steps

• Continue to scale the autonomous lab, Nebula, with a target to double its size in 2026.
• Focus on leading the transition to autonomous research infrastructure integrated with AI models.
• Generate revenue from Solutions, Datapoints, and Cloud Lab businesses on Nebula.
• Continue to monitor and manage cash burn, with a reaffirmed outlook for 2026.

Key Dates

Recommendation

The significant revenue decline is a concern, but the improvement in Adjusted EBITDA and net loss, coupled with a strong cash position and strategic focus on autonomous labs and AI integration, warrants a hold. Further clarity on the impact of restructuring and the trajectory of revenue recovery will be crucial for future recommendations.

Keywords

Ginkgo Bioworks, 8-K, Financial Results, Q1 2026, Autonomous Labs, Biotechnology, Synthetic Biology, Biosecurity